Back to Authors

Gervasi, Stephanie S.

https://orcid.org/0000-0003-4829-6915

Mayo Clinic

Lyme Disease Biobank, Portland, Oregon, USA

Citations 1

The Lyme Disease Biobank: Characterization of 550 Patient and Control Samples from the East Coast and Upper Midwest of the United States
Horn, Elizabeth J. , Dempsey, George, Schotthoefer, Anna M. , Prisco, U. Lena, McArdle, Matthew, Gervasi, Stephanie S. , Golightly, Marc G., Luca, Cathy De, Evans, M. B., Pritt, Bobbi S. , Theel, Elitza S. , Iyer, Radha, Liveris, Dionysios , Wang, Guiqing , Goldstein, Don, Schwartz, Ira , Pritt, Bobbi S , Horn, Elizabeth J , Dempsey, George

Journal of Clinical Microbiology | February 24, 2020 | Volume: 58 | Issue: 6 | Pages: No page available

10.1128/jcm.00032-20 Get It

Lyme disease (LD) is an increasing public health problem. Current laboratory testing is insensitive in early infection, the stage at which appropriate treatment is most effective in preventing disease sequelae. The Lyme Disease Biobank (LDB) collects samples from individuals with symptoms consistent with early LD presenting with or without erythema migrans (EM) or an annular, expanding skin lesion and uninfected individuals from areas of endemicity. Samples were collected from 550 participants (298 cases and 252 controls) according to institutional review board-approved protocols and shipped to a centralized biorepository.